A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood
This study is testing a new vaccine and immune system treatments for children with a serious type of brain tumor called DIPG or DMG. The goal is to see if this combination is safe and helps the body's immune system fight the cancer.
Children between 1 and 18 years old who were recently diagnosed with DIPG or DMG and finished radiation therapy 6 to 10 weeks ago may be able to join. Participants cannot have received certain chemotherapy drugs during radiation or have other major health issues like active infections.
Participants will receive a specialized vaccine designed for their tumor type along with two immunotherapy drugs that help boost the immune system. Doctors will closely monitor safety and how well the treatments are tolerated throughout the study.
The study is currently recruiting patients at medical centers in Orange, California; Chicago, Illinois; and Boston, Massachusetts.
- 1Evaluates a specialized vaccine and immunotherapy for children with certain brain tumors
- 2Open to patients aged 1 to 18 who recently completed radiation therapy
- 3Currently recruiting at multiple hospital locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.